The DOI matches its Crossref record.
Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber
Abstract
OBJECTIVES: To test the hypothesis that intranasal levocabastine (LEVO) may provide benefits as a oncedaily treatment in allergic rhinitis (AR), this non-inferiority study compared the effect at steady state of once- and twice-daily dosing with LEVO on allergen-induced nasal symptoms in AR patients. METHODS: This was a randomized, double-blind, three-way cross over study evaluating the effects of repeat doses of LEVO 200 µg once-daily, LEVO 200 µg twice-daily (total dose 400 µg) and placebo, all via intranasal spray, in 78 AR patients. The primary endpoint was weighted mean total nasal symptom score (TNSS) during a 4-hour allergen exposure in the Environmental Exposure Chamber measured at trough pharmacokinetic levels either 12 (LEVO twice-daily) or 24 (LEVO once-daily) hours post-dose. RESULTS: After 7 days dosing, the difference in weighted mean TNSS (0-4 hours) following LEVO once-daily versus twice-daily was 0.23 units (95% CI -0.36, 0.82), demonstrating noninferiority between the two LEVO dosing regimens by meeting the pre-specified criterion of an upper limit of 95% CI<1.0. Both dosing regimens of LEVO resulted in a statistically significant reduction in mean TNSS compared with placebo (adjusted mean difference from placebo: LEVO once-daily: -1.12 (95% CI -1.71, -0.53); LEVO twice-daily: -1.35 (-1.94, -0.76)), meeting the pre-specified criterion for superiority (upper limit of 95% CI<0). All treatments were well-tolerated. CONCLUSIONS: The results of this study support the hypothesis that at steady state LEVO 200 µg taken once-daily provides similar benefit to LEVO 200 µg dosed twice-daily.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the given level of technical and clinical validation, ACCs have been intensively used in clinical drug development to study pharmacological properties of new drugs during phase II trials, such as dose-finding,1039-1041 onset of action,1042-1046 and duration of action.1047-1049”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1048]
Citations
Cites
Still being checked.
Cited by
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Liu, J., Liang, Q., Oldham, M. J., Rostami, A. A., Wagner, K. A., Gillman, I. G., Patel, P., Savioz, R., & Sarkar, M. A. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14090969 · Cited by 45
Self-citationAlmutairi, F. M., Ajmal, M. R., Siddiqi, M. K., Majid, N., Alalawy, A. I., Abdelhameed, A. S., & Khan, R. H. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1750486 · Cited by 5
Chronische Rhinosinusitis im Kindesalter
Mainz, J. G., Arnold, C., Tabori, H., & Gerber, A. R. (2016) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-016-0063-5 · Cited by 3
Metadata
- Authors
- Murdoch, R. D., Bareille, P., Ignar, D., Mark, S., Miller, S. R., Gupta, A., Salapatek, A.-M., & Patel, P.
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2015-10-01
- Volume
- 53
- Issue
- 10
- Pages
- 811-818
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2473809525
- Cited by
- 6
- References
- 0
- Citations by year
- 2023: 1 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 1
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Clinical Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- levocabastine, allergic rhinitis, once-daily dosing, twice-daily dosing, dosing regimen comparison, nasal spray, allergen challenge, nasal symptom score, non-inferiority, steady-state pharmacokinetics, antihistamines
- MeSH terms
- Adult, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Piperidines, Cross-Over Studies, Histamine H1 Antagonists, Non-Sedating, Young Adult, Rhinitis, Allergic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber. https://app.cochat.ai/papers/10.5414/cp202389
- The paper
- Murdoch, R. D., Bareille, P., Ignar, D., Mark, S., Miller, S. R., Gupta, A., Salapatek, A.-M., & Patel, P. (2015). Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp202389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.